GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Altimmune Inc (NAS:ALT) » Definitions » Earnings per Share (Diluted)

Altimmune (Altimmune) Earnings per Share (Diluted) : $-1.61 (TTM As of Mar. 2024)


View and export this data going back to 2005. Start your Free Trial

What is Altimmune Earnings per Share (Diluted)?

Altimmune's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-0.34. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.61.

Altimmune's EPS (Basic) for the three months ended in Mar. 2024 was $-0.34. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.61.

Altimmune's EPS without NRI for the three months ended in Mar. 2024 was $-0.34. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.61.

During the past 3 years, the average EPS without NRIGrowth Rate was 9.30% per year. During the past 5 years, the average EPS without NRI Growth Rate was 18.30% per year. During the past 10 years, the average EPS without NRI Growth Rate was 34.60% per year.

During the past 13 years, Altimmune's highest 3-Year average EPS without NRI Growth Rate was 69.40% per year. The lowest was -5.90% per year. And the median was 32.10% per year.


Altimmune Earnings per Share (Diluted) Historical Data

The historical data trend for Altimmune's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Altimmune Earnings per Share (Diluted) Chart

Altimmune Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.60 -1.91 -2.35 -1.81 -1.66

Altimmune Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.40 -0.32 -0.39 -0.56 -0.34

Competitive Comparison of Altimmune's Earnings per Share (Diluted)

For the Biotechnology subindustry, Altimmune's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Altimmune's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Altimmune's PE Ratio distribution charts can be found below:

* The bar in red indicates where Altimmune's PE Ratio falls into.



Altimmune Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Altimmune's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-88.447-0)/53.247
=-1.66

Altimmune's Earnings Per Share (Diluted) for the quarter that ended in Mar. 2024 is calculated as

Diluted Earnings Per Share (Q: Mar. 2024 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-24.394-0)/70.802
=-0.34

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Altimmune  (NAS:ALT) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Altimmune Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Altimmune's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Altimmune (Altimmune) Business Description

Industry
Traded in Other Exchanges
Address
910 Clopper Road, Suite 201S, Gaithersburg, MD, USA, 20878
Altimmune Inc is engaged on developing treatments for obesity and liver diseases. The Company's pipeline includes next generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.
Executives
David Drutz director 8601 SIX FORKS ROAD, SUITE 160, RALEIGH NC 27615
Richard I Eisenstadt officer: Chief Financial Officer 4819 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Catherine A. Sohn director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Matthew Scott Harris officer: Chief Medical Officer C/O ALTIMMUNE, INC., 910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG MD 20878
Raymond M Jordt officer: Chief Business Officer ALTIMMUNE, INC., 910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG MD 20878
Wayne Pisano director C/O PROVENTION BIO, INC., P.O. BOX 666, OLDWICK NJ 08858
Vipin K Garg director, officer: President and CEO 4819 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
John Gill director C/O PHARMATHENE, INC, ONE PARK PLACE, SUITE 450, ANNAPOLIS MD 21401
M Scot Roberts officer: Chief Scientific Officer 910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG MD 20878
Diane Jorkasky director 60 MANOR AVENUE, WELLESLEY MA 02482
Philip Hodges director 19 FIRSTFIELD RD., SUITE 200, GAITHERSBURG MD 20878
Vhcp Management Iii, Llc 10 percent owner 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Venrock Healthcare Capital Partners Ii, L.p. 10 percent owner 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Venrock Healthcare Capital Partners Iii, L.p. 10 percent owner 530 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10036
Vhcp Co-investment Holdings Iii, Llc 10 percent owner 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018